Accessibility Menu
Regnum logo

Regnum(OTC) RGMP

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-100%
1 Month-99%
$0.00
+0.00%
+0.00Today
Regnum last closing stock price
MetricPriceDate
Last closeUSD 0.002024-07-12
Regnum stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99%USD 0.002024-02-16
1 month-99%USD 0.002024-02-16
3 month-99%USD 0.002024-02-16
Year to date-99.98%USD 0.012023-10-16
1 year-100%USD 0.152023-06-14
3 year-100%USD 0.422021-06-29
5 year-100%USD 0.202019-07-12
Since inception-100%USD 0.152019-05-29

Regnum Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$705.00K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.86 (Low)

Price

$0.00

Volume

3,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jul 22, 2024

RGMP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Regnum

Regnum Corp. is focused on developing and marketing therapeutic agents aimed at treating rare and infectious diseases. The company's flagship product, Leronlimab (PRO 140), is a monoclonal antibody designed to inhibit HIV from entering human cells. Headquartered in New York, Regnum Corp. operates as a subsidiary of Phoenixus AG.

Products and Services
  • Leronlimab (PRO 140) for HIV treatment
  • Research and development of innovative therapeutic agents
  • Focus on rare and infectious diseases
Growth Outlook
  • Potential market expansion as HIV treatment options evolve
  • Increased interest in monoclonal antibodies in healthcare
  • Strategic partnerships may enhance research capabilities
Financial Highlights
  • Recent quarterly net income of -$202,000
  • Cash and cash equivalents of $462,374 as of March 31, 2023
  • Trailing twelve months (TTM) revenue remains at $0
Regnum Corp. operates in the biotechnology sector, emphasizing the development of innovative treatments for significant health challenges. The company's flagship product, Leronlimab, represents a promising approach to HIV treatment, which could position Regnum favorably in a competitive market. Despite recent financial challenges, including a net loss in the latest quarter, the company maintains a focus on research and development, which may lead to future growth opportunities. The current cash position provides a foundation for ongoing operations and potential strategic initiatives. Investors may find interest in the company's commitment to addressing unmet medical needs in the healthcare landscape.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Employees

2

CEO

Anne Kirby, MBA

Headquarters

New York City, NY 10016, US

RGMP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

101.39%

Return on Capital

-186.44%

Return on Assets

-90.32%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.95M

Volume

3.00K

Avg. Volume

0

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$648.00K

EBITDA

-$124.78K

Operating Cash Flow

-$937.73K

Capital Expenditure

$0.00

Free Cash Flow

-$937.73K

Cash & ST Invst.

$462.37K

Total Debt

$1.57M

Regnum Performance Analysis

Regnum annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
Regnum sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-30N/A
Q32022-09-30N/A
Q42022-12-31N/A
Q12023-03-31N/A
Regnum annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.01N/A
20222022-12-31USD -0.03193.1%
Regnum sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-3025.6%
Q32022-09-3011.1%
Q42022-12-3125.0%
Q12023-03-31-66.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

1

N/A

Net Income

-$202.00K

+27.3%

EBITDA

$324.00

+181.4%

Quarterly Fundamentals

Name
Q1 2023YOY CHG

Total Cash

$462.37K

-67.0%

Total Debt

$1.57M

+3.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.57M

+3.0%

Return on Assets

-90.32%

N/A

Return on Invested Capital

63.41%

N/A

Free Cash Flow

-$320.50K

-262.9%

Operating Cash Flow

-$320.50K

-262.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMPEAmpio Pharmaceuticals, Inc.
$0.18+0.00%
IRBSIR Biosciences Holdings Inc.
$0.00+0.00%
BIOAFBioasis Technologies Inc.
$0.00+0.00%
GBLXGB Sciences, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About RGMP

What is the current price of Regnum?

Regnum is trading at $0.00 per share.

What is the 52-week range for Regnum?

Over the past 52 weeks, Regnum has traded between $0.00 and $0.00.

How much debt does Regnum have?

As of the most recent reporting period, Regnum reported total debt of $1.56M.

How much cash does Regnum have on hand?

Regnum reported $782.87K in cash and cash equivalents in its most recent financial results.

What is Regnum’s dividend yield?

Regnum does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.